Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 3/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5010797 | 1.00 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL28905992 | 0.98 | P2RX7 (0.65) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL129457 | 0.98 | P2RX7 (0.65) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Ammonia Solution, Strong SCHEMBL28560460 | 0.96 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL28331539 | 0.96 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Fluoride SCHEMBL22032488 | 0.96 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL22032483 | 0.93 | P2RX7 (0.56) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL22032484 | 0.92 | P2RX7 (0.59) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Cyanide SCHEMBL28204544 | 0.92 | P2RX7 (0.59) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL29082826 | 0.91 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10864207-B2 | Method of treating endothelial dysfunction | Celagenex Research (India) Pvt. Ltd. (IN) | 2020-12-15 | — | — | US | claimed |
| US-20200222383-A1 | POTENT SYNERGISTIC COMPOSITIONS OF VASOACTIVE MEDIATORS ENHANCERS FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION | Celagenex Research (India) Pvt. Ltd. (IN) | 2020-07-16 | — | — | US | claimed |
| WO-2020141552-A1 | POTENT SYNERGISTIC COMPOSITIONS OF VASOACTIVE MEDIATORS ENHANCERS FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION | Celagenex Research (India) Pvt. Ltd. (IN) | 2020-07-09 | — | — | WO | claimed |
| US-20240350456-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY CONDITIONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118302145-A | Cosmetic water-in-oil emulsion comprising a specific water-soluble UV screening agent, a base, a volatile oil, a hydrophobic film-forming polymer, a polyoxyalkylene-alkylated linear polydimethylsiloxane and vitamin B3 | 莱雅公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4370092-A2 | A NON-THERAPEUTIC COSMETIC METHOD FOR REDUCING WRINKLES ON A SKIN SURFACE | L'OREAL (FR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117355289-A | Non-therapeutic cosmetic method for reducing wrinkles on the surface of the skin | 莱雅公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116655528-A | Preparation method of 1-methyl nicotinoyl ammonium chloride | 宁波百思佳医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023094277-A1 | COSMETIC WATER-IN-OIL EMULSION COMPRISING A SPECIFIC WATER-SOLUBLE UV SCREENING AGENT, A BASE, A VOLATILE OIL, A HYDROPHOBIC FILM-FORMING POLYMER, A POLYOXYALKYLENATED LINEAR POLYDIMETHYLMETHYLSILOXANE AND A VITAMIN B3 | L'OREAL (FR) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023286879-A2 | A NON-THERAPEUTIC COSMETIC METHOD FOR REDUCING WRINKLES ON A SKIN SURFACE, A KIT FOR IMPLEMENTING THE METHOD, AND A METHOD OF USING A KIT | L'OREAL (FR) | 2023-01-19 | — | — | WO | disclosed |
| CN-110087609-B | Water-in-oil emulsion containing baicalin, xanthine base, vitamin B3, and polyvalent metal cation salt | 莱雅公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-3558216-A1 | WATER-IN-OIL EMULSION CONTAINING BAICALIN, A XANTHINE BASE, A VITAMIN B3, AND A POLYVALENT METAL CATION SALT | L'Oréal (FR) | 2019-10-30 | — | — | EP | disclosed |
| CN-110087609-A | Containing scutelloside, xanthine bases, vitamin B3 and multivalent metal cation salt water-in-oil emulsion | 莱雅公司 | 2019-08-02 | — | — | CN | disclosed |
| WO-2019115289-A1 | COMPOSITION OF GEL/GEL TYPE BASED ON PIGMENTS, AT LEAST ONE SATURATED LINEAR C3-C8 DIHYDROXYALKANE AND SALICYLIC ACID IN FREE FORM | L'OREAL (FR) | 2019-06-20 | — | — | WO | disclosed |
| CN-108473478-A | TBK/IKK inhibitor compounds and uses thereof | 默克专利有限公司 | 2018-08-31 | — | — | CN | disclosed |
| WO-2018114213-A1 | WATER-IN-OIL EMULSION CONTAINING BAICALIN, A XANTHINE BASE, A VITAMIN B3, AND A POLYVALENT METAL CATION SALT | L'OREAL (FR) | 2018-06-28 | — | — | WO | disclosed |
| CN-107847499-A | Methods of treating neurodegenerative diseases | 阿速万科学有限责任公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864207-B2 | Method of treating endothelial dysfunction | NNMT, NOS1, NOS2 | PARP1 4044/4885P2RX7 3516/4885MKNK1 789/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | PARP1 255/4885P2RX7 306/4885MKNK1 2912/4885 |
| US-20200222383-A1 | POTENT SYNERGISTIC COMPOSITIONS OF VASOACTIVE MEDIATORS ENHANCERS FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION | NNMT, NOS1, NOS2 | PARP1 4204/4885P2RX7 3900/4885MKNK1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.